KHN922 / Chengdu Kanghong Pharma - LARVOL DELTA

A novel dual-payload HER3-directed antibody-drug conjugate, shows potent antitumor efficacy in HER3-low in vivo tumor models (AACR 2025) - "To date, patritumab deruxtecan (U3-1402) is the only HER3-targeting therapy that has demonstrated clinical efficacy in both non-small cell lung cancer. The non-GLP toxicity study in cynomolgus monkeys provided evidence of the favorable safety profile of KHN922, the highest non-severely toxic dose (HNSTD) is 50 mg/kg/dose.In summary, KHN922, an ADC with dual toxins and unique mechanisms of action, displayed superior anti-tumor effects, the ability to overcome treatment-resistance and tumour recurrences, and an acceptable safety profile in preclinical studies. These findings support the potential of KHN922 as a promising advanced therapeutic candidate for HER3 tumors."

ADC • Preclinical • Bladder Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ERBB3

First-In-Human Study of KHN922 for Injection (clinicaltrials.gov) - P1/2 | N=276 | Not yet recruiting | Sponsor: Chengdu Kanghong Biotech Co., Ltd.

First-in-human • New P1/2 trial • Oncology • Solid Tumor